Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Up 164.9% in March

Jaguar Health, Inc. (NASDAQ:JAGX) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 19,710,000 shares, a growth of 164.9% from the March 15th total of 7,440,000 shares. Based on an average daily trading volume, of 40,390,000 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Jaguar Health in a research note on Saturday, April 6th. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Jaguar Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC acquired a new position in Jaguar Health during the first quarter worth $1,079,000. Virtu Financial LLC lifted its stake in shares of Jaguar Health by 76.1% in the 1st quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 99,073 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Jaguar Health by 152.3% in the 2nd quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 321,795 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Jaguar Health by 507.3% in the 1st quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 141,796 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Jaguar Health by 141.7% in the 3rd quarter. Vanguard Group Inc. now owns 192,335 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 112,770 shares during the last quarter. Institutional investors and hedge funds own 12.04% of the company’s stock.

Jaguar Health Stock Performance

NASDAQ JAGX opened at $0.12 on Thursday. The stock’s fifty day moving average is $0.08 and its two-hundred day moving average is $0.19. The company has a debt-to-equity ratio of 6.33, a current ratio of 2.00 and a quick ratio of 1.34. Jaguar Health has a fifty-two week low of $0.05 and a fifty-two week high of $1.22.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.